Timothy Chiang

TiGenix - American Depositary Shares (NASDAQ: TIG) is up over 80 percent since the start of the year, sending the stock above BTIG's price target.  The Analyst BTIG analyst Timothy Chiang downgraded shares of TiGenix from Buy to Neutral and removed its price target, as the firm does not...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) reported its Q4 2016 results, with revenue ahead of expectations, and reaffirmed its full-year guidance. Teva is now “aggressively looking” for a new CEO to turnaround the company, BTIG’s Timothy Chiang said in a report. He...

With Mylan NV (NASDAQ: MYL) announcing the launch of generic Concerta earlier than expected in the United States, BTIG’s Timothy Chiang expressed optimism regarding the stock, stating that the company was likely to benefit from this launch. Chiang maintained a Buy rating on the company,...

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) has announced the results from its second pivotal Phase 3 trial for plecanatide in constipation-predominant irritable bowel syndrome (IBS-C), reconfirming the robust efficacy and clean side effect profile of the drug candidate. BTIG’s Timothy Chiang...

BTIG’s Timothy Chiang believes 2017 will be a year filled with volume-growing companies in focus. Chiang maintains a Buy rating on Shire PLC (ADR) (NASDAQ: SHPG), with a price target of $242. Superior Product The analyst believes outperformance in 2017 could be driven by “management...

Before Friday's market open, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced positive data from its first of two Phase 3 trials for clinical constipation-predominant irritable bowel syndrome (IBS-C) drug plecanatide. “We are very pleased with these results,” said Gary S. Jacob,...

After Monday's close, Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Siggi Olafsson, head of global generics at the company, would be retiring at the end of Q1:17. BTIG’s Timothy Chiang maintains a Neutral rating on the company, while expressing surprise regarding the...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) hit a new 52-week low of $37.25 on Tuesday after the company reported its third-quarter results and provided a concerning outlook for the full year given some concerns over its specialty drugs. The stock rebounded slightly on Wednesday...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares surged 25 percent on Tuesday, following the company’s Q2 earnings report. BTIG’s Timothy Chiang maintained a Neutral rating on the company. Cautious Stance “While the tone of management seems to have taken a more positive...

Relypsa Inc (NASDAQ: RLYP) reported that paid prescriptions for Veltassa in hyperkalemia increased to 1,230 in May, from 928 in April, and that 1,385 free starter packs were dispensed, representing a 14 percent increase from April. BTIG’s Timothy Chiang maintained a Buy rating on the...

Relypsa Inc (NASDAQ: RLYP) has released monthly Veltassa prescription trends for April, with paid prescriptions rising to 928 in the fourth full month following the launch of the drug and the company having dispensed 1,216 starter packs. BTIG’s Timothy Chiang maintains a Buy rating on the...

On its 1Q call, Relypsa Inc (NASDAQ: RLYP) highlighted the challenges it had been facing in gaining patient access for its hyperkalemia treatment, Veltassa. BTIG’s Timothy Chiang maintains a Buy rating on the company, while lowering the price target from $45 to $35. Estimates Lowered Chiang...